- Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis
-
Zhang J, Xu DL, Liu XB, Bi SJ, Zhao T, Sui SJ, Ji XP, Lu QH
- KMID: 2374035
- Yonsei Med J.
- 2016 Mar;57(2):321-327.
- doi: 10.3349/ymj.2016.57.2.321
PURPOSE: Increased lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and Rho kinase activity may be associated with atherosclerosis. The principal aim of this study was to examine whether darapladib (a selective Lp-PLA2... -
- CITED
-
- Close
- SHARE
-
- Close
- Association of Lipoprotein-Associated Phospholipase A2 with Characteristics of Vulnerable Coronary Atherosclerotic Plaques
-
Liu YS, Hu XB, Li HZ, Jiang WD, Wang X, Lin H, Qin AQ, Wang YM, Zhao T, Dong ZQ, Zhang M, Lu QH
- KMID: 1058810
- Yonsei Med J.
- 2011 Nov;52(6):914-922.
- doi: 10.3349/ymj.2011.52.6.914
PURPOSE: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory enzyme expressed in atherosclerotic plaques. We investigated the association of circulating Lp-PLA2 with characteristics of vulnerable coronary atherosclerotic plaques. MATERIALS AND METHODS: We... -
- CITED
-
- Close
- SHARE
-
- Close
